peter attia on semaglutide A new study from UC San Diego offers early clinical evidence that semaglutide, a widely used GLP-1 receptor agonist, may slow biological aging. In a randomized, placebo-controlled trial, researchers observed a 9% dr peter attia semaglutide Peter

* Disclaimer - Based on a comparison of studies measuring weight loss with similar BMI measurements over a 8 week period for active Noom Med patients prescribed a GLP-1 medication and active Noom Healthy Weight customers not taking medication

The trial included two doses

Semaglutide is FDA-approved and prescribed under medical supervision to ensure safety and effectiveness

& Pastor, R

Tirzepatide (Mounjaro, Zepbound, compounded) Tirzepatide is a dual GIP/GLP-1 receptor agonist, which means its mechanism differs slightly from pure GLP-1 medications

Why Regulatory Compliance Matters Strong compliance programs help organizations: Reduce enforcement risks Improve inspection readiness Strengthen patient safety protections Support business continuity Protect brand reputation Minimize legal exposure Organizations that proactively address regulatory concerns are generally better positioned for sustainable growth